Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enzymatics has unveiled Archer targeted sequencing technology, which enhances gene mutation identification and discovery with high sensitivity and reduced costs.
Subscribe to our email newsletter
The technology is being announced during the Advances in Genome Biology & Technology (AGBT) conference, which is recognized throughout the sequencing community as a cornerstone for the discussion of genomics research.
Enzymatics chief scientific officer Dr Jason Myers noted the rise of next generation sequencing (NGS) and advances in understanding the complex roles of genetic mutations in disease are creating a wealth of new opportunities for molecular detection in disease diagnosis, biomarker detection, drug discovery and development, and biomedical research.
"Existing technologies, however, have not been sufficiently robust, scalable or cost-effective to support expanded use of sequencing. Archer Targeted Sequencing Technology addresses the growing need for novel NGS based assays. Archer captures and amplifies only gene targets of interest and offers dramatic enhancements in scalability, mutation detection speed, complex mutation identification and reduced costs," Dr Myers added.
Archer targeted sequencing technology is based on Anchored Multiplex PCR (AMP) and proprietary Archer analysis pipeline software. AMP is a new and innovative method that offers rapid, economical and scalable targeted library construction for NGS.
The software analyzes sequence data and generates a simple, multitiered report of all mutations in the target sequences and does not require any programming expertise.
Enzymatics obtained Archer technology in 2013 when it acquired ArcherDx.
The Archer ALK, RET, ROS1 Fusion Detection Kit is a targeted sequencing assay that simultaneously detects and identifies fusions of human ALK, RET and ROS1 genes for oncology research.
Archer kits, including the ALK, RET, ROS1 kit, feature the efficient, lyophilized AMP assay, require only tens of nanograms of total nucleic acid isolated from FFPE, fresh frozen tissue or blood, and are 100% compatible with both Ion Torrent and Illumina sequencing platforms. Total hands-on time for eight samples is less than 70 minutes.
In addition to the Archer ALK, RET, ROS1 Fusion Detection Kit, Enzymatics offers oncology researchers the opportunity to develop their own custom Archer assays for a variety of applications including RNA gene fusion detection, RNA abundance, copy number variation, single nucleotide variants and insertion/deletion detection.
Proprietary assay design software selects the ideal AMP primers. The company’s rapid development of assays enables custom kits to be shipped within three weeks.